Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Investor Presentation (April 2011)

33 slides from Questcor Pharmaceuticals's investor presentation, Apr 5, 2011

  1. Slide 1: Questcor

    (\W QUESTCOR’

  2. Slide 2: NASDAQ: QCOR April 2011

    NASDAQ: QCOR April 2011 NASDAQ: QCOR April 2011

  3. Slide 3: Safe Harbor Statement

    3 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa

  4. Slide 4: Questcor: A biopharmaceutical company

    4 Questcor A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions

  5. Slide 5: Questcor Overview

    Questcor Overview Flagship Product: • Profitable, cash flow positive, $122M in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Infantile Spasms, Nephrotic Syndrome • Combined market opportunity exceeds $1.5 billion Strategy: • Grow Acthar sales in each key market Financi

  6. Slide 6: Preliminary Metrics

    6 • MS New, Paid Scripts: >500 – Up over 115% YOY and 40% sequentially • NS New, Paid Scripts: ~18 • IS New, Paid Scripts: ~88 (in the normal range) • First quarter vials shipped: 2,010 • Medicaid reserves continue to appear adequate • 884,300 shares repurchased Q1 2011 Preliminary Metrics MS New, P

  7. Slide 7: History of Acthar

    History of Acthar 1950 2000 2010 7 1952 First Approved 1968-1973 DESI Review Label Expands 1950 1978 MS Indication Added 2000 2001 Questcor Acquires Acthar 2010 Label Modernized 19 Indications 2007 Questcor Changes Strategy 2010

  8. Slide 8: Significant Barriers to Entry

    Significant Barriers to Entry 8

  9. Slide 9: Sell More Acthar

    9 Sell More Acthar Multiple Sclerosis (MS) Infantile Spasms (IS) Nephrotic Syndrome (NS) Multiple Sclerosis (MS) Infantile Spasms (IS) Nephrotic Syndrome (NS)

  10. Slide 10: Large Market Opportunity

    Large Market Opportunity ~$66M ~$41M ~$3M ~$5M *Represents estimated net sales market opportunity based on internal company estimates ** Represents approximate 2010 Net Sales by therapeutic area based on internal company estimates 10 ~$66M ~$41M ~$3M ~$5M $1B+ MS Sales IS Sales NS Sales $500M to $2B

  11. Slide 11: Acthar and MS

    Acthar and MS Inadequate Response to Steroids Poor Venous Access Problematic Steroid Side Effects Acthar when “Steroids are not suitable” *Based on prescription data 11 Neurodegenerative disorder Acute treatment for relapses Dosing period is 1-2 weeks* $40K-$50K/Rx Inadequate Response to Steroids Po

  12. Slide 12: MS Sales - Record of Consistent Growth

    12 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which

  13. Slide 13: Multiple Sclerosis Potential Market

    13 Multiple Sclerosis $500M to $2B+ Potential Market *Based on internal company estimates. $500M to $2B+ $500M to $2B+ Potential Market Potential Market

  14. Slide 14: MS Trends

    14 • Q1-2011 results – Q1-11 new paid Rxs up >115% vs. Q1-10 – MS sales well over 50% of QCOR sales – Over $75M annualized run-rate • Growing number of Acthar prescribers – But only ~400 out of 8,000 neurologists • Speakers bureau growing MS Trends Q1-2011 results – Q1-11 new paid Rxs up >115% vs. Q

  15. Slide 15: MS Sales Calls vs. Paid New Rxs

    15 MS Sales Calls vs. Paid New Rxs *MS call data approximate MS Calls MS Calls MS Rxs MS Rxs 1000 2000 3000 4000 5000 6000

  16. Slide 16: Sales Force Expansion

    16 • Doubled sales force: 38 to 77 sales reps • Newly expanded sales force began call activity Nov 1 – Significant increase in calls on MS-treating neurologists – Also targeting certain child neurologists for IS sales calls • MS paid Rxs increasing since November – December set new record – February

  17. Slide 17: Infantile Spasms

    17 • Devastating, refractory form of childhood epilepsy – Very poor developmental outcome if inadequately treated • Not responsive to standard anti-epileptic drugs • Ultra-rare orphan disorder – 1,500 to 2,000 patients annually • Typically occurs in children less than 2 years old • Characterized by

  18. Slide 18: Acthar and IS

    18 • Used by over half of child neurologists • FDA approval 10/15/10 – 7 year orphan exclusivity for IS indication • Crisis therapy • Treatment for 2-4 weeks* • In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks

  19. Slide 19: IS Sales Plan

    19 • Significant variability in quarterly prescriptions • Q1-2011 sales within historic range • Promotion effort began 11/1/10 • Potential to increase IS revenue – Acthar currently used to treat 30-50% of IS patients IS Sales Plan Significant variability in quarterly prescriptions Q1-2011 sales with

  20. Slide 20: Nephrotic Syndrome

    20 • Characterized by excessive spilling of protein from the kidney into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options Nephrotic Syndrome Characterized by excessive spilling of protein from the kidney int

  21. Slide 21: Acthar and NS

    21 • FDA-approved on label indication for reduction of proteinuria in: – Idiopathic types of nephrotic syndrome • Idiopathic membranous nephropathy • Focal segmental glomerular sclerosis (FSGS) • IgA nephropathy – Lupus nephritis • Treatment for 4-6 months* • $150K-250K/Rx Acthar and NS *Based on pr

  22. Slide 22: Proof of Concept Data

    22 • Available November 2010 • Case series showed response from Acthar in refractory idiopathic membranous nephropathy (on-label) – 9 of 11 patients met response criteria • Positive signal received in diabetic nephropathy investigator initiated trial (not on-label) – 9 of 15 patients on Acthar met r

  23. Slide 23: R&D Effort in NS

    23 • Dose response trial for idiopathic membranous nephropathy (on-label) – $5-7M multi-center trial, n~100 – Reduction of proteinuria is endpoint • Presently designing a well controlled study in collaboration with FDA for diabetic nephropathy (off- label) – Proof-of-concept study with different dos

  24. Slide 24: NS Business Plan

    24 • Hired 5 reps to sell Acthar to nephrologists – Initiated sales efforts in early March 2011 – Develop selling process and generate sales – Expand selling effort if sales increase • Peer review publication of case series in March 2011 – Drug Design, Development and Therapy • Q1 2011 NS Scripts: ~

  25. Slide 25: Immediate Acthar Growth Opportunities

    25 • MS - Build on sales momentum, lots of market headroom • IS - Incremental market share growth • NS - Establish Acthar as a therapeutic alternative in this sizeable market Immediate Acthar Growth Opportunities Yellow bars: Estimated net sales market opportunity based on internal company estimates

  26. Slide 26: Financials

    26 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive

  27. Slide 27: 2010 Financial Results

    27 2010 Financial Results Record Sales (up 30%) and Solid Earnings (EPS up 35%) Net Sales ($M) Gross Margin Operating Inc ($M) EPS $ 115.1 93% $53.8 $0.54 $88.3 92% $41.2 $0.40 2010 2009 Record Sales (up 30%) and Solid Earnings (EPS up 35%) Net Sales ($M) Gross Margin Operating Inc ($M) EPS $ 115.1

  28. Slide 28: Questcor is Cash Flow Positive

    Questcor is Cash Flow Positive Cash / ST Investment Accounts Receivable $122M* $12M 3/31/11 28 Debt-free balance sheet *After return of $78 million of cash to shareholders through share repurchases . Cash / ST Investment Accounts Receivable $122M* $12M 3/31/11 Debt-free balance sheet

  29. Slide 29: Share Repurchases

    29 Share Repurchases: 15 Million Shares • 2.2 Million Preferred shares repurchased • 13.3 Million Common shares repurchased • $78 million returned to shareholders in stock buybacks • 61.7 million shares currently outstanding • 4.3 million shares remain on buyback authorization Repurchases significan

  30. Slide 30: Go Forward Plan - Sell More Acthar

    • Expanded sales force to pursue MS/IS • Dedicated pilot NS sales team started March 2011 • Develop other markets for Acthar – Acthar is its own pipeline with 15 other on-label and many possible other therapeutic uses – Further define and develop the unique characteristics of Acthar • No business de

  31. Slide 31: Investment Highlights

    31 • Questcor is streamlined, focused & profitable • Acthar has sustainable competitive advantages • Focus on substantial growth in MS sales • Recent IS approval/label modernization • Possible upside with NS • Market sizes have good growth potential • Cash flow positive/no debt Investment Highlights

  32. Slide 32: April 2011

    NASDAQ: QCOR April 2011 32 NASDAQ: QCOR April 2011

  33. Slide 33: Questcor

    (NW QUESTCOR’

Questcor Pharmaceuticals — Investor Presentation (April 2011) on 6ix